Long term (7yr) follow up of LYMA trial - @LysaLymphoma rituximab maintenance study after autoSCT in MCL by clementine sarkozy - continued PFS benefit, no OS difference, and no increase of relapse after R discontinuation, but continued unmet need in POD24 population #ICML23 #17ICML

Pity to see this Burkitt lymphoma study close early - means we will likely never have a definitive answer to this question (As highlighted by Prof Seymour Haematology Peter MacCallum CC & Royal Melbourne) A reminder of the challenges of running a trial on a highly aggressive rare disease #17ICML

Great news for our patients #lymsm #bmtsm

Happy to share PROs & Cons of CD30 CAR T cell tx in heavily pre-tx'd pts w/ R/R CD30+ lymphomas. Tx was overall well tolerated w/ patient reported outcomes showing recovery to at least their baseline 1mo post-tx. Thx to patients, Natalie Grover, MD, @SeroBMT1, & UNC Lineberger!

⁦Joshua Zeidner MD⁩ speaking at the first annual Thomas Shea clinical cancer symposium on immune modulation in#AML. Great meeting in honor of a great leader and mentor in the field. ⁦UNC Lineberger⁩

Enjoying the annual Thomas C. Shea symposium. UNC Lineberger Joshua Zeidner MD Daniel Pollyea Natalie Grover, MD Brandi Reeves

It was a true honor & privilege to be part of the first annual Shea Symposium UNC Lineberger which was a huge success epitomizing the impact Tom has had on our field & all of us in our careers.

Amazing way to close #SheaSymposium with @sairah__ahmed giving an excellent roadmap and overview of the current treatment armamentarium and future directions of CAR T cell therapy in lymphoma 👏👏👏UNC Lineberger

Delighted to share our work now published on behalf of all co-authors. Our practice has changed- minimal use of HD-MTX in CNS prophylaxis in aNHL. Thank you so much to all international collaborators! ascopubs.org/doi/10.1200/JC…

Multiple Jewish friends (physicians) are now recommending Magen David Adom as a reliable source for donations to #Israel. #onctwitter, I feel as if we could stock an ambulance for $10k or help process donated blood for $7500. #hemetwitter, you want in, too? afmda.org/urgentneeds/

Hodgkin Lymphoma therapy continues to evolve and we need to know more from experts Drs Sairah Ahmed Andy Evens and Natalie Grover, MD #lymsm #ASH23 Saturday 4:00- 5:15 p.m Convention Center, Ballroom 20CD ASH

Trial Spotlight: #COG led Phase 3 trial AHOD2131 studying Newly Diagnosed Stage 1 & 2 Classic Hodgkin Lymphoma in Childrens and Young Adults is available across the #NCI #NCTN networks Cancer Trials Support Unit SWOG Cancer Research Network Alliance for Clinical Trials in Oncology ECOG-ACRIN Cancer Research Group NRG Oncology @NCICTEP_ClinRes ClinicalTrials.gov